Diabetes Care

Important Updates to the Standards of Medical Care in Diabetes--2022 Incorporate New Evidence

Retrieved on: 
Tuesday, May 31, 2022
Medical diagnosis, Physician, Cardiovascular disease, Knowledge, Education, Diabetes Care, American College, American Diabetes Association, Efficacy, Multimedia, Policy, Health, Gestational diabetes, Epidemiology, Quality of life, Review, Standard of care, Section 10 of the Canadian Charter of Rights and Freedoms, Prediabetes, Risk management, Kidney disease, Research, ADA, Health care, Section 11 of the Canadian Charter of Rights and Freedoms, Program, American College of Cardiology, LinkedIn, Safety, Roy Taylor (scientist), Update, Diagnosis, Life, Live, Medical device, Pharmaceutical industry, Diabetes, Patient, Facebook, Instagram, Twitter

ARLINGTON, Va., May 31, 2022 /PRNewswire/ -- Today, the American Diabetes Association (ADA) published important updates to the Standards of Medical Care in Diabetes2022(Standards of Care) , in annotations as the Living Standards of Care .

Key Points: 
  • ARLINGTON, Va., May 31, 2022 /PRNewswire/ -- Today, the American Diabetes Association (ADA) published important updates to the Standards of Medical Care in Diabetes2022(Standards of Care) , in annotations as the Living Standards of Care .
  • The Living Standards of Care are available immediately online at Diabetes Care .
  • The complete, annotated Standards of Care, which includes updates made today, can be accessed online at Diabetes Care.
  • The Abridged Standards of Medical Care in Diabetes has also been updated and can be accessed online at Clinical Diabetes .

New study validates predictive biomarkers in diabetic kidney disease, an important step in precision medicine.

Retrieved on: 
Tuesday, May 3, 2022
EGFR, Type 2 diabetes, ACCORD, Emeritus, Kidney disease, LDT, Biomarker, Kidney, Patient, Geisel School of Medicine, University of Zambia School of Medicine, Advanced glycation end-product, Diabetes Care, Risk, Glycated hemoglobin, Dartmouth, Precision medicine, Sex, CEO, Multimedia, Pharmaceutical industry, Diabetes

LEBANON, N.H., May 3, 2022 /PRNewswire/ -- Journey Biosciences, Inc. A new study recently published in the journal Diabetes Care continues to validate the role that specific biomarkers - advanced glycation endproducts (AGEs) - in predicting if a person with diabetes will develop kidney disease. This personalized assessment builds on the developing field of precision medicine in diabetes.

Key Points: 
  • This personalized assessment builds on the developing field of precision medicine in diabetes.
  • Journey Biosciences Founder and Chief Scientific Officer, Paul Beisswenger, is a lead author of the study.
  • The study used two large cohorts of patients with type 2 diabetes undergoing intensive glucose-lowering therapies over a significant period of time to determine if AGEs were predictive of diabetic kidney disease.
  • The investigators found that the primary endpoint of a 30%
    reduction in kidney function (eGFR) was significantly associated with a higher AGE score.

Diabeloop Presents New Real-Life Results of DBLG1® System

Retrieved on: 
Thursday, April 28, 2022
Solution, Intelligence, Artificial intelligence, Life, DOI, Diabetes, CEO, Personality, T1D, Patient, Glycated hemoglobin, GLOBE, ATTD, Insight, Diabetes Care, Quality of life, Technology, Dizziness, Meal, Data, WP7, Spotify, Hypoglycemia, Conditional sentence, University, AID, Come, Medical device, Pharmaceutical industry, Health insurance

PARIS, April 28, 2022 (GLOBE NEWSWIRE) -- At ATTD 2022 - Diabeloop, a pioneer in therapeutic artificial intelligence for diabetes management, presents today new results from a real-life cohort in Germany.

Key Points: 
  • PARIS, April 28, 2022 (GLOBE NEWSWIRE) -- At ATTD 2022 - Diabeloop, a pioneer in therapeutic artificial intelligence for diabetes management, presents today new results from a real-life cohort in Germany.
  • DBLG1 users in Germany included in the real-life cohort benefit from basic support at initialization.
  • This demonstrates the ease of use of Diabeloop's automated and personalized insulin delivery system and its interface.
  • DOI: 10.1016/S2589-7500(19)30003-2
    3) C. Amadou et al., Diabeloop DBLG1 Closed-loop system enables patients with Type 1 diabetes to significantly improve their glycemic control in real-life situations without serious adverse events, Diabetes Care 2021 Jan; dc201809.

Treatment Developed by CHOP Researchers Prevents Hypoglycemia in Children with Hyperinsulinism

Retrieved on: 
Wednesday, April 13, 2022
Patient, Lists of diseases, Pancreas, Glucagon, Population, Philadelphia, Research, CHOP, Glucose, ATP, National Center for Research Resources, Prussia, Birth defect, Hospital, HI, Insulin, Hypoglycemia, Health, Division, Congenital hyperinsulinism, Fasting, Gene, Glutamine, Children's Hospital of Philadelphia, Mutation, Disease, DOI, Hyperinsulinism, National Center for Spinal Disorders, Diabetes, Clifford, Pharmaceutical industry, Vaccine, MD, Endocrinology, Diabetes Care, Child

PHILADELPHIA, April 13, 2022 /PRNewswire/ -- Researchers at Children's Hospital of Philadelphia (CHOP) have shown that a targeted treatment they developed is effective at controlling blood sugar in patients with hyperinsulinism (HI), a genetic disease in which the pancreas produces too much insulin. The findings, which were published today in Diabetes Care, provide further evidence that the treatment could prevent hypoglycemia in patients with HI and may preclude the need for a full removal of their pancreas, a current standard treatment for severe diffuse HI.

Key Points: 
  • Congenital HI is the most common cause of persistent hypoglycemia in infants and children.
  • In prior studies, CHOP researchers have shown that administering exendin-(9-39), which blocks the GLP-1 receptor, through an intravenous infusion significantly increased fasting glucose levels in adolescents and adults with the KATPHI form of the disease.
  • The researchers found that exendin-(9-39) resulted in a 76% reduction in likelihood of fasting hypoglycemia in the mid-dose group and by 84% in the group receiving the highest dose.
  • They found administering exendin-(9-39) during the protein challenge resulted in an 82% reduction in the likelihood of hypoglycemia.

You've Had COVID-19. Should You Still Get Vaccinated? A CDC-Epic Collaboration Provides the Latest Insight

Retrieved on: 
Wednesday, April 13, 2022
Center, Antimicrobial stewardship, Korea Disease Control and Prevention Agency, Myocarditis, The New England Journal of Medicine, Population, CDC, COVID-19, Pediatrics, Morbidity and Mortality Weekly Report, MD, Infection, Disease, Vaccination, Vaccine, Violence, Diabetes Care, Public health, Multimedia, Decision-making, Risk, Hospital, Severe acute respiratory syndrome coronavirus 2, Research, Pharmaceutical industry, Cosmos, Epic

VERONA, Wis., April 13, 2022 /PRNewswire/ -- In a new Morbidity and Mortality Weekly Report published by the Centers for Disease Control and Prevention (CDC), researchers from the CDC and Epic found that among people previously infected with SARS-CoV-2, vaccination offers the best protection against reinfections that result in hospitalizations. This finding is consistent with previous evidence that vaccination-induced immunity combined with infection-induced immunity provides better protection than infection-induced immunity alone. The new report presents an analysis of data from Epic's Cosmos database, a large electronic health record database that is broadly representative of the U.S. population.

Key Points: 
  • This finding is consistent with previous evidence that vaccination-induced immunity combined with infection-induced immunity provides better protection than infection-induced immunity alone.
  • The new report presents an analysis of data from Epic's Cosmos database, a large electronic health record database that is broadly representative of the U.S. population.
  • Cosmos allows researchers to study 138 million deidentified patient records that account for more than 4 billion healthcare encounters nationwide.
  • To learn more about Cosmos and Epic, visit https://cosmos.epic.com/ and www.epic.com/about
    View original content to download multimedia: https://www.prnewswire.com/news-releases/youve-had-covid-19-should-you-s...

BD Appoints Shana Neal as Chief People Officer

Retrieved on: 
Wednesday, February 23, 2022
Acqui-hiring, Biophysical environment, Human resources, BDX, Health, Therapy, Caesars Entertainment (2020), Communication, Twitter, Inhuman Resources, Efficiency, Socially responsible investing, Neal, Culture, 2025, Owens & Minor, Becton, Industry, Company, Organization, Becton, Dickinson and Company headquarters, Shana, NYSE, CareFusion, Safety, Disease, Diabetes Care, Fortune 500, Equity, LinkedIn, Engagement, Inclusion, Leadership, Patient, HR, Solution, CEO, Pharmaceutical industry, Management, Social, Science

FRANKLIN LAKES, N.J., Feb. 23, 2022 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that Shana Neal has been appointed chief people officer, effective April 4, 2022.

Key Points: 
  • FRANKLIN LAKES, N.J., Feb. 23, 2022 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that Shana Neal has been appointed chief people officer, effective April 4, 2022.
  • Neal replaces Betty Larson who has been named to a new role in the health care industry.
  • "I'm proud to welcome Shana back to BD as our new chief people officer, which is a key role to empower our teams to deliver on our purpose as we advance our BD 2025 strategy and create value for all of our stakeholders."
  • For more information on BD, please visit bd.com or connect with us on LinkedIn at www.linkedin.com/company/bd1/ and Twitter @BDandCo .

Patients Receiving Virta’s Diabetes Reversal Treatment See Sustained Reduction in Depressive Symptoms, New Research Shows

Retrieved on: 
Wednesday, February 2, 2022
Diabetes, Pharmaceutical, Health, Mental Health, Insulin, Diagnosis, Risk, Patient, Diabetes, HIV disease progression rates, Insomnia, International Journal of Behavioral Medicine, Conditional sentence, A1C, Physician, American Diabetes Association, Clinical research, Twitter, Depression, Grammatical mood, Behavioral medicine, Type 2 diabetes, Technology, Research, ZF, Journal, CDC, Mental health, T2D, Health, Doctor of Philosophy, Self-management, Yeshiva University, FDA, Multimedia, Lists of Palestinian rocket attacks on Israel, PTSD, Associate, Weight loss, Pharmaceutical industry, Diabetes Care, Virta

Virta Health , the leader in type 2 diabetes reversal, announced promising results on the impact of its diabetes reversal treatment on depressive symptoms.

Key Points: 
  • Virta Health , the leader in type 2 diabetes reversal, announced promising results on the impact of its diabetes reversal treatment on depressive symptoms.
  • The research, published in The Journal of Behavioral Medicine , highlights rapid and sustained improvement in depressive symptoms during treatment, with nearly one-third fewer patients meeting the clinical cutoff for depression at two years.
  • View the full release here: https://www.businesswire.com/news/home/20220202005670/en/
    According to Virtas latest research, patients receiving its diabetes reversal treatment improved both depressive symptoms and metabolic health simultaneously.
  • According to research published in Diabetes Care , patients with T2D that are experiencing depressive symptoms are much less likely to adhere to diabetes treatment recommendations, leading to worse outcomes.

ADA and ADCES Update National Standards for Diabetes Self-Management Education and Support

Retrieved on: 
Thursday, January 20, 2022
Centers for Disease Control and Prevention, Research, Prediabetes, Nursing, Literature, Diabetes, Magnuson-Stevens Act Provisions; National Standard Guidelines, BSN, Center, Person, ADA, LinkedIn, RN, National, Health, Epidemiology, Outline, Educational specialist, DNP, Population, MBA, Knowledge, Life, Science, TSO, Health equity, Review, American Diabetes Association, Update, National standards, Time, Medicare, Program, Caregiver, Pharmacist, Education, Self-management, Quality of life, Association, Workforce, Risk, Communication, Physician, Medical device, Medicine, Pharmaceutical industry, Diabetes Care, Instagram, Facebook, Twitter

ARLINGTON, Va. and CHICAGO, Jan. 20, 2022 /PRNewswire/ --New updates to the National Standards for Diabetes Self-Management Education and Support (National Standards) call for addressing health equity by improving access to diabetes self-management education and support (DSMES) services, a renewed focus on increasing and maintaining person-centered care and reducing administrative burden.

Key Points: 
  • ARLINGTON, Va. and CHICAGO, Jan. 20, 2022 /PRNewswire/ --New updates to the National Standards for Diabetes Self-Management Education and Support (National Standards) call for addressing health equity by improving access to diabetes self-management education and support (DSMES) services, a renewed focus on increasing and maintaining person-centered care and reducing administrative burden.
  • "The National Standards for DSMES provide diabetes care and education specialists with structure to guide their services.
  • "These updates reflect research for diabetes education and support, behavioral health, clinic and health care environment, technical, and sustainability of business practice."
  • ADCES is an interdisciplinary professional membership organization dedicated to improving prediabetes, diabetes, and cardiometabolic care through innovative education, management, and support.

Latest ADA Annual Standards of Care Includes Changes to Diabetes Screening, First-Line Therapy, Pregnancy, and Technology

Retrieved on: 
Monday, December 20, 2021
Government budget balance, Doctor of Philosophy, Health, Adult, Cardiovascular disease, Review, Student, Fatty liver disease, Epidemiology, Update, Physician, Technology, Diagnosis, Standard of care, Public health, Life, Knowledge, COVID-19, American Diabetes Association, Education, Health care, Research, Prediabetes, Medicine, MD, ACC, Quality of life, Program, PPC, American College, Webcast, ADA, GDM, Endocrinology, Risk management, Multimedia, Gestational diabetes, World Diabetes Day, Medical device, Dentistry, Pharmaceutical industry, Twitter, Diabetes Care, Diabetes, Facebook

ARLINGTON, Va., Dec. 20, 2021 /PRNewswire/ --Today, the American Diabetes Association (ADA) released its much-anticipated annual Standards of Medical Care in Diabetes (Standards of Care) .

Key Points: 
  • ARLINGTON, Va., Dec. 20, 2021 /PRNewswire/ --Today, the American Diabetes Association (ADA) released its much-anticipated annual Standards of Medical Care in Diabetes (Standards of Care) .
  • Based upon the latest scientific diabetes research and clinical trials, Standards of Care is the gold-standard for professionals in the medical field and includes vital new and updated practice guidelines to care for people with diabetes and prediabetes.
  • The 2022 Standards of Care is now live online in Diabetes Care and is published as a supplement to the January 2022 issue ofDiabetes Care.
  • Topics covered are of interest to clinically oriented physicians, researchers, epidemiologists, psychologists, diabetes care and education specialists, and other health care professionals.

John Martinson Joins StatLab as New Chief Operating Officer

Retrieved on: 
Tuesday, December 14, 2021
Medical Supplies, Supply Chain Management, Manufacturing, Other Health, Health, Medical Devices, Research, Other Manufacturing, Retail, Science, Chemicals, Plastics, Business administration, History, Martinson, Mechanical engineering, Plant, Histology, Family, LeMoyne–Owen College, SVP, Honeywell, Bayer, Clarkson University, Bayer Corporation, Pathology, VP, Investment, COO, Diabetes Care, Immunohistochemistry, Global Operations, Management, Pharmaceutical industry, Science

StatLab Medical Products , a leading developer and manufacturer of diagnostic supplies and equipment, is pleased to announce the addition of John Martinson to its management team as Chief Operating Officer (COO).

Key Points: 
  • StatLab Medical Products , a leading developer and manufacturer of diagnostic supplies and equipment, is pleased to announce the addition of John Martinson to its management team as Chief Operating Officer (COO).
  • His energy and history of managing teams in transition across multiple sites will be an immediate asset to our organization.
  • Martinson will be responsible for overseeing all manufacturing and supply chain operations at StatLab.
  • Founded in 1976, StatLab Medical Products is leading the way in development and manufacturing of high-quality histology, cytology, molecular, and immunohistochemistry diagnostic products.